Nonalcoholic Steatohepatitis in Hepatocarcinoma: New Insights about Its Prognostic Role in Patients Treated with Lenvatinib.

M. Rimini,M. Kudo,T. Tada,S. Shigeo, W. Kang,G. Suda,A. Jefremow,V Burgio,M. Iavarone,R. Tortora,F. Marra,S. Lonardi,E. Tamburini,F. Piscaglia,G. Masi,G. Cabibbo,F. G. Foschi,M. Silletta,T. Kumada,H. Iwamoto, T. Aoki, M. J. Goh,N. Sakamoto,J. Siebler,A. Hiraoka,T. Niizeki,K. Ueshima,T. Sho,M. Atsukawa,M. Hirooka,K. Tsuji,T. Ishikawa,K. Takaguchi,K. Kariyama,E. Itobayashi, K. Tajiri,N. Shimada, H. Shibata,H. Ochi,S. Yasuda,H. Toyoda,S. Fukunishi,H. Ohama,K. Kawata,J. Tani,S. Nakamura,K. Nouso,A. Tsutsui, T. Nagano, T. Takaaki,N. Itokawa, T. Okubo,T. Arai,M. Imai,K. Joko,Y. Koizumi,Y. Hiasa,A. Cucchetti,F. Ratti,L. Aldrighetti,S. Cascinu,A. Casadei-Gardini

ESMO open（2021）

引用 21|浏览9

暂无评分

关键词

advanced hepatocarcinoma,nonalcoholic steatohepatitis,lenvatinib,sorafenib,immunotherapy,atezolizumab,bevacizumab,hepatitis C,hepatocellular carcinoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要